NCNP-02
- Generic Name
- NCNP-02
NS-089/NCNP-02-201 in Boys With Duchenne Muscular Dystrophy (DMD)
- First Posted Date
- 2023-08-16
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- NS Pharma, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT05996003
- Locations
- 🇺🇸
Children's Hospital Colorado, Aurora, Colorado, United States
🇺🇸Rare Disease Research, Atlanta, Georgia, United States
🇺🇸Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
Extension Study of NS-089/NCNP-02 in DMD
Phase 2
Active, not recruiting
- Conditions
- Duchenne Muscular Dystrophy (DMD)
- Interventions
- First Posted Date
- 2021-11-26
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Nippon Shinyaku Co., Ltd.
- Target Recruit Count
- 6
- Registration Number
- NCT05135663
- Locations
- 🇯🇵
Kagoshima University Hospital, Kagoshima, Japan
🇯🇵National Center of Neurology and Psychiatry, Tokyo, Japan
Exploratory Study of NS-089/NCNP-02 in DMD
- First Posted Date
- 2019-10-16
- Last Posted Date
- 2022-09-29
- Lead Sponsor
- National Center of Neurology and Psychiatry, Japan
- Target Recruit Count
- 6
- Registration Number
- NCT04129294
- Locations
- 🇯🇵
National Center of Neurology and Psychiatry, Kodaira, Tokyo, Japan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath